# Immunotherapy of Natural Killer(NK) Cells in Human T Lymphotropic Virus Type 1(HTLV-1) Associated Myelopathy(HAM)

> **NCT02961712** · PHASE1 · UNKNOWN · sponsor: **The Second Affiliated Hospital of Fujian Medical University** · enrollment: 15 (estimated)

## Conditions studied

- HAM

## Interventions

- **BIOLOGICAL:** NK cells
- **BIOLOGICAL:** amniotic epithelial cells

## Key facts

- **NCT ID:** NCT02961712
- **Lead sponsor:** The Second Affiliated Hospital of Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-07
- **Primary completion:** 2017-10
- **Final completion:** 2017-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2017-04-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02961712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02961712, "Immunotherapy of Natural Killer(NK) Cells in Human T Lymphotropic Virus Type 1(HTLV-1) Associated Myelopathy(HAM)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02961712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*